S-1/A: Aethlon Medical Seeks Up to $7 Million in Best-Efforts Offering to Fund Hemopurifier Development

Aethlon Medical is offering up to 5,228,758 shares of common stock and accompanying warrants in a best-efforts offering to fund research and development of its Hemopurifier device.

Summary

• Aethlon Medical, Inc. is conducting a best-efforts offering of up to 5,228,758 shares of common stock and accompanying warrants to purchase an equal number of shares.
• Pre-funded warrants are also being offered as an alternative to common stock for investors who might exceed ownership limits.
• Each share or pre-funded warrant comes with a warrant to purchase one share of common stock, exercisable immediately and expiring in five years.
• The offering will terminate on May 20, 2024, unless terminated earlier at the company's discretion.
• Maxim Group LLC is acting as the exclusive placement agent, but is not obligated to purchase any securities.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol AEMD, with a last reported sale price of $1.53 per share on April 23, 2024.
• The offering price will be determined between Aethlon and the investors at the time of pricing and may be at a discount to the current market price.
• The company intends to use the net proceeds for general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital.
• If the company were to receive net proceeds of $7.00 million from this offering, the company believes that the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments as of December 31, 2023, would be sufficient to fund our planned operations through September 2025.
• The company completed a 1-for-10 reverse stock split on October 4, 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential of the Hemopurifier and the company's ongoing clinical trials, it also acknowledges significant risks, including the uncertainty of raising sufficient capital and the substantial doubt about the company's ability to continue as a going concern. The best-efforts nature of the offering and the potential for dilution further contribute to a cautious sentiment.

Positives

• The offering aims to provide capital for the continued development of the Hemopurifier technology.
• The company has flexibility in using the proceeds for various corporate purposes.
• Pre-funded warrants offer an alternative investment option for certain investors.
• The company believes that net proceeds of $7.00 million from this offering, together with our existing cash, cash equivalents and short-term investments as of December 31, 2023, would be sufficient to fund our planned operations through September 2025.

Negatives

• The offering is on a best-efforts basis, meaning there's no guarantee of raising the full amount.
• The offering price may be at a discount to the current market price.
• There is no established trading market for the warrants or pre-funded warrants.
• The company has broad discretion in the use of the net proceeds and may not use them effectively.
• The company may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• Purchasers in this offering will suffer immediate dilution in their investment.
• Future sales of substantial amounts of the company's common stock could adversely affect the market price.
• Holders of warrants and pre-funded warrants will have no rights as a common stockholder until they acquire common stock.
• The warrants may not have any value.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will need to raise additional capital to fund its operations in the future.
• The current volatility in the equity markets, coupled with the trading price of our common stock create additional challenges to raising a sufficient amount of capital through an equity financing in the near term.
• Potentially changing circumstances, including those related to inflation, recent bank failures and ongoing military conflicts may also result in the depletion of our capital resources more rapidly than we currently anticipate.

Future Outlook

The company expects to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. If the company were to receive net proceeds of $7.00 million from this offering, the company believes that the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments as of December 31, 2023, would be sufficient to fund our planned operations through September 2025.

Industry Context

Aethlon Medical is operating in the medical therapeutic industry, specifically focusing on developing the Hemopurifier, a device targeting cancer, viral infections, and organ transplantation. The company is pursuing Breakthrough Device designation from the FDA for its device, which could expedite the development and review process. The company is also conducting clinical trials in Australia and India, and is working with contract research organizations (CROs) to manage these trials.

Comparison to Industry Standards

• It is difficult to compare Aethlon Medical directly to industry standards due to its unique Hemopurifier technology and focus on a broad spectrum of applications.
• However, companies like Cytosorbents Corporation, which develops blood purification technologies, could be considered a comparable company.
• Cytosorbents has achieved commercial success with its CytoSorb adsorber, which is used in critical care settings to reduce cytokine storm and other inflammatory mediators.
• Aethlon's Hemopurifier aims to remove viruses, exosomes, and other harmful substances from the blood, which could potentially address a wider range of conditions than CytoSorb.
• Other companies in the exosome space, such as Exosome Diagnostics (acquired by Bio-Techne), are focused on developing diagnostic tools based on exosomes, while Aethlon is focused on therapeutic applications.
• In the organ transplantation field, companies like TransMedics are developing organ care systems to improve organ preservation and viability.
• Aethlon's Hemopurifier could potentially complement these systems by removing harmful substances from recovered organs prior to transplantation.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees' job security is tied to the company's ability to secure funding and continue operations.
• The success of the Hemopurifier could potentially benefit patients with cancer, viral infections, and those in need of organ transplantation.
• The company's suppliers and creditors are subject to the risk of the company's potential inability to continue as a going concern.

Next Steps

• Complete the offering of common stock and warrants.
• Continue research and development of the Hemopurifier.
• Conduct clinical trials in Australia and India.
• Work with the FDA to qualify a second supplier of GNA.
• Monitor the impact of inflation, recent bank failures, and military conflicts on the business.

Key Dates

Keywords

Aethlon Medical, Hemopurifier, common stock, warrants, pre-funded warrants, offering, clinical trials, research and development, capital raise, oncology, viral infections